MedTrace Logo

Tablet Ginger Versus Tablet Doxylamine Succinate in Control of Nausea and Vomiting in Pregnancy

NCT06772974 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-01-17

No results posted yet for this study

Summary

Nausea and vomiting are common GI symptoms of pregnancy. Multiple managing options have been used for NVP. Doxylamine succinate is used as first line treatment for NVP despite that alternative modalities such as ginger extracts and tablets is being explored.

This RCT will be conducted after taking ethical approval and informed consent, in Department of Gynecology, Aziz Bhatti Shaheed teaching hospital, Gujrat. Patients will be divided into two equal groups. One group will receive tablet ginger while other group will receive Doxylamine succinate tablets. Baseline PUQE score (3- 15 point scale) over 24 hour will be noted according to symptoms of nausea and vomiting following 7 days of treatment and then at 2nd and 3rd week. Comparison of the change in the severity of nausea from baseline scores (Post-therapy PUQE score - base line scores) in both groups will be considered for results.

Conditions

  • Nausea Gravidarum
  • Hyperemesis Gravidarum

Interventions

DRUG

Doxylamine Succinate USP

Tab. Doxylamine Succinate

DIETARY_SUPPLEMENT

Ginger

Ginger (zingiber officinale)

Sponsors & Collaborators

  • University of Gujrat

    collaborator OTHER

  • Nawaz Sharif Medical College

    lead OTHER

Principal Investigators

  • Syeda Shaista Waheed Professor, MBBS, FCPS · Nawaz Sharif Medical College, Gujrat

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2025-06-30
Completion
2025-07-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06772974 on ClinicalTrials.gov